Skip to main content

Advertisement

SpringerLink
Log in

Hotline update of clinical trials and registries presented at the at the European Society of Cardiology Congress in Paris 2011

  • Clinical trial update and hotline sessions
  • Published:
Clinical Research in Cardiology Aims and scope Submit manuscript

Abstract

This article provides information and commentaries on trials which were presented at the Hotline and Clinical Trial Update Sessions during the Late Breaking Clinical Trial Sessions European Society of Cardiology Congress, held in Paris, France, from 27th to 31st August 2011. This article gives an overview on a number of novel clinical trials in the field of cardiovascular medicine, which were presented. The data have been presented by leading experts in the accordant field with relevant positions in the trials. Unpublished reports should be considered as preliminary data as the analysis may change in the final publications. The comprehensive summaries have been generated from the oral presentation and the webcasts of the European Society of Cardiology, similar as previously reported (Lenski et al. in Clin Res Cardiol Off J Ger Card Soc 99: 679–692, 2010) and should provide the readers with the most comprehensive information of relevant publications. The data were presented by leading experts in the field with relevant positions in the trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Lenski M, Mahfoud F, Werner C, Bauer A, Böhm M (2010) Hotline sessions and clinical trial updates presented at the European Society of Cardiology Congress in Stockholm 2010. Clin Res Cardiol Off J Ger Card Soc 99:679–692

    Google Scholar 

  2. Yusuf S. Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, Gupta R, Kelishadi R, Iqbal R, Avezum A, Kruger A, Kutty R, Lanas F, Lisheng L, Wei L, Lopez-Jaramillo P, Oguz A, Rahman O, Swidan H, Yusoff K, Zatonski W, Rosengren A, Teo KK, on behalf of the Prospective Urban Rural Epidemiology (PURE) Study Investigators (2011) Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. doi:10.1016/S0140-6736(11)61215-4

  3. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J (2009) Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302:1993–2000

    Article  PubMed  CAS  Google Scholar 

  4. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM (2007) Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 298:309–316

    Article  PubMed  CAS  Google Scholar 

  5. Zilversmit DB (1979) Atherogenesis: a postprandial phenomenon. Circulation 60:473–485

    PubMed  CAS  Google Scholar 

  6. Mega JL (2011) A new era for anticoagulation in atrial fibrillation. N Engl J Med. doi:10.1056/NEJMe1109748

  7. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151

    Article  PubMed  CAS  Google Scholar 

  8. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, ROCKET AF Investigators (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891

    Article  PubMed  CAS  Google Scholar 

  9. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, ARISTOTLE Committees and Investigators (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. doi:10.1056/NEJMoa1107039

  10. Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD, Gersh BJ, Granger CB, Hanna M, Horowitz J, Hylek EM, McMurray JJ, Verheugt FW, Wallentin L, ARISTOTLE Investigators (2010) Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 159:331–339

    Article  PubMed  CAS  Google Scholar 

  11. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E (1993) A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 69:236–239

    PubMed  CAS  Google Scholar 

  12. Imazio M, Brucato A, Cemin R, Ferrua S, Belli R, Maestroni S, Trinchero R, Spodick DH, Adler Y, on behalf of the CORP (COlchicine for Recurrent Pericarditis) Investigators (2011) Colchicine for recurrent pericarditis (CORP) a randomized trial. Ann Intern Med. doi:10.2459/JCM.0b013e3280110616

  13. Sawada T, Yamada H, Dahlöf B, Matsubara H, KYOTO HEART Study Group (2009) Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J 30:2461–2469

    Article  PubMed  CAS  Google Scholar 

  14. Foundation NK (1997) NKF-DOQI clinical practice guidelines for hemodialysis adequacy. National Kidney Foundation. Am J kidney Dis Off J Natl Kidney Found 30(3 Suppl 2):S15–S66

    Google Scholar 

  15. Messerli FH, Bangalore S, Ruschitzka F (2009) Angiotensin receptor blockers: baseline therapy in hypertension? Eur Heart J 30:2427–2430

    Article  PubMed  Google Scholar 

  16. Sever PS et al (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361(9364):1149–1158

    Article  PubMed  CAS  Google Scholar 

  17. Sever PS, Chang CL, Gupta AK, Whitehouse A, Poulter NR, on behalf of the ASCOT Investigators (2011) The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the UK. Eur Heart J. doi:10.1093/eurheartj/ehr333

  18. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM, West of Scotland Coronary Prevention Study Group (2007) Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 35:1477–1486

    Article  Google Scholar 

  19. Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, Paolini JF, Hankey GJ, Mahaffey KW, Patel MR, Singer DE, Califf RM (2011) Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. doi:10.1093/eurheartj/ehr342

  20. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358:1547–1559

    Article  PubMed  CAS  Google Scholar 

  21. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, EMPHASIS-HF Study Group (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364:11–21

    Article  PubMed  CAS  Google Scholar 

  22. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM (2004) Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350:2140–2150

    Article  PubMed  CAS  Google Scholar 

  23. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi, Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators (2005) The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352:1539–1549

    Article  PubMed  CAS  Google Scholar 

  24. Linde C, Abraham WT, Gold MR, St John Sutton M, Ghio S, Daubert C, REVERSE (REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction) Study Group (2008) Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heartfailure symptoms. J Am Coll Cardiol 52:1834–1843

    Article  PubMed  Google Scholar 

  25. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA 3rd, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W, MADIT-CRT Trial Investigators (2009) Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 361:1329–1338

    Article  PubMed  Google Scholar 

  26. Gervais R, Leclercq C, Shankar A, Jacobs S, Eiskjaer H, Hagemann A, Freemantle N, Cleland J, Tavazzi L, Daubert C (2009) Surface electrocardiogram to predict outcome in candidates for cardiac resynchronization therapy: a sub-analysis of the CARE-HF trial. Eur J Heart Fail 11:699–705

    Article  PubMed  Google Scholar 

  27. Ellenbogen KA, Gold MR, Meyer TE, Lozano IF, Mittal S, Waggoner AD, Lemke B, Singh JP, Spinale FG, Van Eyk J, Whitehill J, Weiner S, Bedi M, Rapkin J, Stein KM (2010) Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in Cardiac Resynchronization Therapy (SMART-AV) trial. Circulation 122:2660–2668

    Article  PubMed  Google Scholar 

  28. Ekman I, Chassany O, Komajda M, Böhm M, Borer JS, Ford I, Tavazzi L, Swedberg K (2011) Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J. doi:10.1093/eurheartj/ehr343

  29. Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, Ali IS, Pohost G, Gradinac S, Abraham WT, Yii M, Prabhakaran D, Szwed H, Ferrazzi P, Petrie MC, O’Connor CM, Panchavinnin P, She L, Bonow RO, Rankin GR, Jones RH, Rouleau JL, STICH Investigators (2011) Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 364:1607–1616

    Article  PubMed  CAS  Google Scholar 

  30. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H (2002) Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 347:969–974

    Article  PubMed  CAS  Google Scholar 

  31. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494–502

    Article  PubMed  CAS  Google Scholar 

  32. Sørensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, Jørgensen C, Madsen JK, Hansen PR, Køber L, Torp-Pedersen C, Gislason GH (2009) Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 374:1967–1974

    Article  PubMed  Google Scholar 

  33. Steffel J, Braunwald E (2011) Novel oral anticoagulants: focus on stroke prevention and treatment of venous thromboembolism. Eur Heart J. doi:10.1093/eurheartj/ehr052

  34. Steg PG, Mehta S, Jukema JV, Lip GYH, Gibson CM, Kovar F, Kala P, Garcia-Hernandez A, Renfurm RW, Granger CB (2011) RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J. doi:10.1093/eurheartj/ehr334

  35. APPRAISE Steering Committee and Investigators, Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, Fox KA, Goodman SG, Harrington RA, Huber K, Husted S, Lewis BS, Lopez-Sendon J, Mohan P, Montalescot G, Ruda M, Ruzyllo W, Verheugt F, Wallentin (2009) Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 119:2877–2885

    Article  PubMed  Google Scholar 

  36. Alexander, JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, De Caterina, R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D, Leiva-Pons JL, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo W, Diaz R, White H, Ruda M, Geraldes M, Lawrence J, Harrington, RH, Wallentin L, for the APPRAISE-2 Investigators (2011) Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. doi:10.1056/nejmoa1105819nejm.org

  37. Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan ES, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson CM, ATLAS ACS-TIMI 46 study group (2009) Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 374:29–38

    Article  PubMed  CAS  Google Scholar 

  38. Gibson CM, Mega JL, Burton P, Goto S, Verheugt F, Bode C, Plotnikov A, Sun X, Cook-Bruns N, Braunwald E (2011) Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. Am Heart J 161:815–821

    Article  PubMed  CAS  Google Scholar 

  39. Perera D, Stables R, Thomas M, Booth J, Pitt M, Blackman D, de Belder A, Redwood S, BCIS-1 Investigators (2010) Elective intra-aortic balloon counterpulsation during high-risk percutaneous coronary intervention: a randomized controlled trial. JAMA 304:867–874

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, 66421, Homburg/Saar, Germany

    K. Walenta, C. Werner & M. Böhm

  2. Medizinische Klinik und Poliklinik II, Universitätsklinikum Bonn, Bonn, Germany

    J. M. Sinning

Authors
  1. K. Walenta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. M. Sinning
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Werner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Böhm
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Walenta.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Walenta, K., Sinning, J.M., Werner, C. et al. Hotline update of clinical trials and registries presented at the at the European Society of Cardiology Congress in Paris 2011. Clin Res Cardiol 100, 955–971 (2011). https://doi.org/10.1007/s00392-011-0370-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00392-011-0370-8

Keywords

Search

Navigation